Revvity to acquire scientific software solutions provider ACD/Labs

This acquisition is expected to deepen Revvity Signals' presence in research informatics and advance its expansion into development and manufacturing solutions

Revvity has entered into a definitive agreement to acquire ACD/Labs to significantly expand the capabilities of its Signals Software portfolio. The transaction is expected to close in late Q4 2025.

The acquisition aims to create a unified Software as a Service (SaaS) environment that connects molecular design, analytical science, and manufacturing quality control, providing end-to-end support across the scientific workflow from discovery to manufacturing.

ACD/Labs brings deep expertise in supporting analytical and process chemistry within pharmaceutical and chemical R&D workflows, including molecular identification, characterization, and quality monitoring. Together, Revvity Signals and ACD/Labs will provide comprehensive support across the scientific workflow—from discovery and development to scale-up and manufacturing— giving scientists the ability to interpret, manage, and act on complex data with greater speed and confidence.

“By integrating ACD/Labs’ technologies into the Revvity Signals platform, we’re giving our customers across pharmaceuticals and material sciences a truly unified SaaS environment—one that connects molecular design, analytical science, and manufacturing quality control within a single, end-to-end solution,” said Kevin Willoe, president of Revvity Signals Software. “This acquisition adds meaningful value to our portfolio and reinforces the importance of analytical sciences as a driver of innovation across disciplines.”

“For more than three decades, our scientists, informaticians, and software developers have been recognized as leaders in analytical and chemical intelligence,” said Daria Thorp, president and CEO of ACD/Labs. “Joining the Revvity Signals team brings together two industry leaders with a shared commitment to innovation in scientific software. Together, we will expand the reach of our technology and deliver unified, end-to-end solutions that empower customers with deeper insight and greater scientific continuity.”